Biotech Values

[DewDiligence]

BIIB receives US dosing patent on Tecfidera (BG-12):

http://finance.yahoo.com/news/us-patent-office-grants-patent-200000286.html

The patent, which will expire in 2028, covers the dosing regimen of daily administration of 480 mg of TECFIDERA. This regimen is included in the proposed marketing application for TECFIDERA, which is currently under review by the U.S. Food and Drug Administration (FDA).

This might be a tough patent to defend. The obvious attack is to claim that there is nothing magical about 480mg—i.e. that a slightly different dose such as 470mg or 490mg would work just as well.